BTLA/B-andT-lymphocyte attenuator/CD272 (Fc fusion)
Selected Variant
E21-D06
Size: 10 µg
Recombinant Human B- and T-Lymphocyte Attenuator is produced by our Mammalian expression system and the target gene encoding Lys31-Leu150 is expressed with a Fc tag at the C-terminus.
Product Specifications
Background
B- and T-Lymphocyte Attenuator (BTLA) is a single-pass type I membrane protein containing 1 Ig-like V-type (immunoglobulin-like) domain. BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a lymphocyte inhibitory receptor that inhibits lymphocytes during immune response. BTLA also is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM) . BTLA-HVEM complexes negatively regulate T-cell immune responses.
Synonyms
B- and T-Lymphocyte Attenuator; B- and T-Lymphocyte-Associated Protein; CD272; BTLA
Expression System
Human cells
Endotoxin
Less than 0.1 ng/ µg (1 IEU/ µg) as determined by LAL test.
Purity
Greater than 95% as determined by reducing SDS-PAGE.
Form
Lyophilized
Shipping Conditions
The product is shipped at ambient temperature.
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4.
Species
Human
Shipping Temperature
Ambient
Price
Sign In for Pricing
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog